Elanco Animal Health agreed to buy Bayer’s veterinary drugs unit in a cash and stock deal valued at $7.6 billion, creating the second-largest maker of medicines for pets and livestock and expanding Elanco’s reach online.
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.
Corindus Vascular Robotics entered into a definitive merger agreement to be acquired by Siemens Healthineers AG for an aggregate purchase price of approximately $1.1 billion.
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.
Shares of Cambrex Corp. were up more than 46 percent in trading after the company announced an agreement to be acquired by an affiliate of the Permira funds for $60 per share, totaling $2.4 billion.
Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.
Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.